Costello, SP, et al. - In this multicenter, randomized, double-blind clinical trial that was conducted across three Australian tertiary referral centers between June 2013 and June 2016, researchers evaluated 73 individuals to assess the efficiency of short-duration fecal microbiota transplantation (FMT) therapy to induce remission in ulcerative colitis (UC) using anaerobically prepared stool. The primary endpoint was steroid-free remission of UC (Mayo score ≤ 2 with an endoscopic Mayo score ≤ 1 at week 8), which was achieved in 12 of the 38 study participants who received pooled donor FMT vs 3 of the 35 participants who received autologous FMT. The investigators observed three serious adverse events in the donor FMT group and two in the autologous FMT group. Approximately 42% of the study participants who achieved the primary end point at week 8 following donor FMT were able to maintain remission at 12 months.